These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7094504)

  • 1. Prediction of steady-state verapamil plasma concentrations in children and adults.
    Wagner JG; Rocchini AP; Vasiliades J
    Clin Pharmacol Ther; 1982 Aug; 32(2):172-81. PubMed ID: 7094504
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Verapamil disposition kinetics in chronic atrial fibrillation.
    Kates RE; Keefe DL; Schwartz J; Harapat S; Kirsten EB; Harrison DC
    Clin Pharmacol Ther; 1981 Jul; 30(1):44-51. PubMed ID: 7237897
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of intravenous and oral verapamil dosing.
    Reiter MJ; Shand DG; Pritchett EL
    Clin Pharmacol Ther; 1982 Dec; 32(6):711-20. PubMed ID: 7140136
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Verapamil kinetics in normal subjects and patients with coronary artery spasm.
    Freedman SB; Richmond DR; Ashley JJ; Kelly DT
    Clin Pharmacol Ther; 1981 Nov; 30(5):644-52. PubMed ID: 7297023
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The pharmacology of verapamil. IV. Kinetic and dynamic effects after single intravenous and oral doses.
    McAllister RG; Kirsten EB
    Clin Pharmacol Ther; 1982 Apr; 31(4):418-26. PubMed ID: 7060323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The pharmacology of verapamil. I. Elimination kinetics in dogs and correlation of plasma levels with effect on the eletrocardiogram.
    McAllister RG; Bourne DW; Dittert LW
    J Pharmacol Exp Ther; 1977 Jul; 202(1):38-44. PubMed ID: 874818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced verapamil clearance during long-term oral administration.
    Shand DG; Hammill SC; Aanonsen L; Pritchett EL
    Clin Pharmacol Ther; 1981 Nov; 30(5):701-6. PubMed ID: 7297027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Verapamil and norverapamil plasma levels in infants and children during chronic oral treatment.
    Piovan D; Padrini R; Svalato Moreolo G; Magnolfi G; Milanesi O; Zordan R; Pellegrino PA; Ferrari M
    Ther Drug Monit; 1995 Feb; 17(1):60-7. PubMed ID: 7725379
    [TBL] [Abstract][Full Text] [Related]  

  • 9. In vivo comparison of putative probes of CYP3A4/5 activity: erythromycin, dextromethorphan, and verapamil.
    Krecic-Shepard ME; Barnas CR; Slimko J; Gorski JC; Wainer IW; Schwartz JB
    Clin Pharmacol Ther; 1999 Jul; 66(1):40-50. PubMed ID: 10430108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An investigation of the cause of accumulation of verapamil during regular dosing in patients.
    Schwartz JB; Abernethy DR; Taylor AA; Mitchell JR
    Br J Clin Pharmacol; 1985 Apr; 19(4):512-6. PubMed ID: 3994898
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Verapamil disposition and cardiovascular effects in elderly patients after single intravenous and oral doses.
    Carosella L; Menichelli P; Alimenti M; Zuccala G; Gemma A; Cocchi A; Carbonin PU
    Cardiovasc Drugs Ther; 1989 Jun; 3(3):417-25. PubMed ID: 2487538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic effects of high-dose continuous intravenous verapamil infusion: clinical experience in the intensive care unit.
    De Cicco M; Macor F; Robieux I; Zanette G; Fantin D; Fabiani F; Nicolosi G; Fracasso A; Toffoli G; Santantonio C; Lestuzzi C; Matovic M; Boiocchi M
    Crit Care Med; 1999 Feb; 27(2):332-9. PubMed ID: 10075058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Physiological pharmacokinetics and pharmacodynamics of (+/-)-verapamil in female rats.
    Todd EL; Abernethy DR
    Biopharm Drug Dispos; 1987; 8(3):285-97. PubMed ID: 3593905
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prolongation of verapamil elimination kinetics during chronic oral administration.
    Schwartz JB; Keefe DL; Kirsten E; Kates RE; Harrison DC
    Am Heart J; 1982 Aug; 104(2 Pt 1):198-203. PubMed ID: 7102502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The pharmacokinetics of racemic verapamil in patients with impaired renal function.
    Zachariah PK; Moyer TP; Theobald HM; Frantz RP; Kurtz SB; McCarthy JT; Smith RL
    J Clin Pharmacol; 1991 Jan; 31(1):45-53. PubMed ID: 2045528
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of verapamil in patients with hypertension.
    Anderson P; Bondesson U; de Faire U
    Eur J Clin Pharmacol; 1986; 31(2):155-63. PubMed ID: 3803414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics, bioavailability and ECG response of verapamil in patients with liver cirrhosis.
    Somogyi A; Albrecht M; Kliems G; Schäfer K; Eichelbaum M
    Br J Clin Pharmacol; 1981 Jul; 12(1):51-60. PubMed ID: 7248141
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of verapamil: experience with a sustained intravenous infusion regimen.
    Reiter MJ; Shand DG; Aanonsen LM; Wagoner R; McCarthy E; Pritchett EL
    Am J Cardiol; 1982 Oct; 50(4):716-21. PubMed ID: 7124631
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Lack of interaction between verapamil and cimetidine.
    Abernethy DR; Schwartz JB; Todd EL
    Clin Pharmacol Ther; 1985 Sep; 38(3):342-9. PubMed ID: 4028631
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacokinetics of verapamil in patients with atrial fibrillation.
    Anderson P; BondessoN U; Sylvén C
    Eur J Clin Pharmacol; 1982; 23(1):49-57. PubMed ID: 7128672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.